Embed Size (px)
Citation preview
Therapeutic approach Target: Shock reversal
Systemic Hyperinflammation in Cardiac Surgery Protect Your Surgery Results
With CytoSorb you can pursue these therapeutic targets:(supported by clinical and preclinical * data)
CytoSorb Therapy – REGAIN CONTROL
Modulation of immune response (1)
Stabilization of hemodynamics (1,2)
Improvement in organ functions (1,2)
Reduction in complications (3)
Preoperative triggersPreexisting hyperinflammation: • Shock• Endocarditis
Intraoperative triggersSurgical complexity and patient comorbidity:• Aortic surgery• Transplantations• Complex Redo- and combination procedures• Chronic liver and/or renal dysfunction
Postoperative triggersComplications:• Sepsis• ECMO• Post-CPB-hyperinflammation• Vasoplegic shock
Broad adsorption spectrumEasy and safe CytoSorb Therapy
• Inflammatory mediators incl. DAMPs and PAMPs (e.g. enterotoxins) (1,7,8)
• Bilirubin, myoglobin, free hemoglobin (4,5,6,10)
• Quick integration into HLM, CRRT and ECMO circuits • No activation of coagulation and complement system• No relevant elimination of albumin and platelets (9)
The appropriate concept for every situation: CytoSorb
To reduce inflammatory activation in high-risk patients/surgery with HLM
To regain control in organ dysfunction caused by hyperinflammation
Intraoperative use Postoperative use
Visit http://literature.cytosorb.com for an overview of all references
CytoSorbents Europe GmbH
Müggelseedamm 13112587 Berlin | Germany T +49 30 65 49 91 45 F +49 30 65 49 91 46 [email protected]
CytoSorbents Switzerland GmbH
c/o MGM GmbH Wielandstrasse 5 | 4153 Reinach BL | Switzerland T +41 61 713 73 78F +41 61 713 73 79 [email protected]
CytoSorb and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. B1002R04EN2019 © Copyright 2019,
CytoSorbents Europe GmbH. All rights reserved.
www.cytosorb.com
CytoSorb should only be administered by personnel who have been properly trained in administration of extracorporeal therapies.
CytoSorb is not available for commercial sale in USA.
References (* preclinical data):1. Traeger K et al., Int J Artif Organs 2016; 39(3): 141 - 62. Traeger K et al., Int J Artif Organs 2017; 40(5): 240 - 93. Deppe AC et al., Z Herz-Thorax-Gefäßchir 2016; 30(4): 254 - 94. Faenza S et al., Crit Care 2016; 20(Suppl 2):P192 *5. Buettner S et al., Blood Purif 2017; 44(1): 30 - 16. Traeger K et al., EuroELSO. Glasgow 20167. Gruda M et al., PLoS One 2018; 13(1):e0191676 *
8. Venkataraman R et al., Blood Purif 2004; 22: 143 - 9 *9. Bernardi MH et al., Crit Care 2016; 20(1): 9610. Kuntsevich VI et al., Artif Cells Blood Subset Biotechnol 2009; 37(1): 45 - 7 *
